Physician profile
Robert N Tracy
NPI 1003848763
$1,066.86
in general payments reported to CMS, 2019-2025
28 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $14.25 · 2021: $199 · 2022: $99.74 · 2023: $150 · 2024: $207 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $210.24 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $121.15 | 2021-2024 | Ubrelvy |
| Smith+Nephew, INC. | $104.22 | 2019 | |
| Dexcom, INC. | $81.02 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $80.95 | 2019-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Novo Nordisk INC | $78.75 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.19 | 2022-2025 | |
| Amgen INC. | $29.89 | 2019-2024 | Otezla, Repatha |
| Gilead Sciences, INC. | $26.42 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.40 | 2019-2021 | |
| Sage Therapeutics, LLC | $21.19 | 2025 | Zurzuvae |
| Ultragenyx Pharmaceutical INC. | $21.04 | 2024 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $20.41 | 2019 | |
| Lilly USA, LLC | $20.26 | 2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.99 | 2024 | Synjardy, Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.34 | 2021 | |
| Axsome Therapeutics, INC. | $15.34 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $14.97 | 2022 | |
| Insulet Corporation | $14.57 | 2019 | |
| Amarin Pharma, INC. | $14.25 | 2020 | |
| Pfizer INC. | $13.90 | 2023 | |
| Horizon Therapeutics Plc | $13.76 | 2019 | |
| Glaxosmithkline, LLC. | $12.74 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.64 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.47 | 2019 | |
| Dynavax Technologies Corporation | $8.72 | 2019 | |
| Mayne Pharma Commercial LLC | $6.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tracy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.